1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lahiri, P | 1 |
Chaudhuri, U | 1 |
Chattopadhyay, A | 1 |
Dasgupta, AK | 1 |
1 other study available for 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Article | Year |
---|---|
Platelet aggregation profile as a marker of hydroxyurea bioavailability through nitric oxide generation in chronic myelogenous leukemia.
Topics: Adult; Biological Availability; Blood Platelets; Cyclic GMP; Enzyme Inhibitors; Female; Humans; Hydr | 2006 |